Can Azithromycin Cause Vaginal Yeast Infections?
Yes, azithromycin can cause vaginal yeast infections (vulvovaginal candidiasis), with documented incidence rates of 1-2% in clinical trials, and this risk is highest within the first 2-3 weeks after treatment.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for azithromycin explicitly lists vaginitis as a documented adverse effect 1:
- Single 1-gram dose: Vaginitis occurs in 1% of patients
- Single 2-gram dose: Vaginitis occurs in 2% of patients
- Multiple-dose regimens: Monilia and vaginitis listed as genitourinary side effects occurring at ≤1% frequency
Additionally, post-marketing surveillance reports oral and vaginal candidiasis (oral moniliasis) as recognized adverse events 1.
Clinical Evidence Supporting the Association
Timing and Magnitude of Risk
The risk of developing vaginal candidiasis after azithromycin follows a specific temporal pattern. The highest risk occurs in week 2 after starting antibiotics, with a relative risk of 10.70 compared to non-antibiotic users 2. The risk remains significantly elevated in weeks 1 and 3 as well. This postmarketing surveillance study of 31,588 women demonstrated that azithromycin specifically increases vaginal candidiasis risk when compared to antidepressants as a control group 2.
Dose-Response Relationship
A case-control study of 684 women with symptomatic vulvovaginal candidiasis found that antibiotic use in the preceding month increased the odds of VVC by 1.75-fold (95% CI 1.33-2.32) 3. Importantly, the likelihood of VVC was directly related to the duration of antibiotic use, and the risk was higher in women with a history of recurrent Candida infections 3.
Quantified Risk in Prospective Studies
A prospective pilot study provides the most concrete risk estimates: among women taking short-course oral antibiotics, 37% (10/27) developed positive Candida cultures during follow-up compared to 11% (3/27) in controls (RR 3.33, p=0.03) 4. More clinically relevant, 22% (6/27) developed symptomatic VVC versus 0% in controls 4.
Mechanism: Disruption of Vaginal Microbiota
Azithromycin's effect on vaginal yeast infections stems from its disruption of the protective vaginal microbiota. Research shows that after azithromycin treatment for Chlamydia trachomatis, the vaginal microbiota becomes dominated by Lactobacillus iners rather than more protective Lactobacillus species 5. This shift creates a "nonoptimal" vaginal environment that is more susceptible to Candida overgrowth 5.
Notably, 75% of women with chlamydial infections already have high-risk vaginal microbiota (dysbiotic communities), and azithromycin treatment does not restore optimal microbiota composition 6. This persistent dysbiosis maintains susceptibility to both yeast infections and reinfection with sexually transmitted pathogens.
Clinical Implications and Risk Stratification
Highest Risk Patients
- Women aged 36-40 years (RR 6.0 for symptomatic VVC) 7
- Those with history of recurrent vulvovaginal candidiasis 3
- Women requiring longer antibiotic courses 3
- Those with pre-existing vaginal dysbiosis
Important Caveats
Baseline Candida colonization does not predict who will develop symptomatic VVC after antibiotics 4. Approximately 14% of asymptomatic women have positive vaginal Candida cultures at baseline, but this does not reliably identify those who will become symptomatic after antibiotic exposure 4.
The risk applies across antibiotic classes—no specific antibiotic type (including azithromycin specifically) shows differential risk compared to other antibiotics in most studies 3, though cephalosporins may have the highest attributable risk (12.8%) 7.
Practical Management Approach
When prescribing azithromycin, particularly single high-dose regimens (1-2 grams):
- Counsel patients that vaginal yeast infection is a recognized side effect occurring in 1-2% of women
- Inform patients that symptoms typically develop within 2-3 weeks if they occur
- Consider prophylactic antifungal therapy in women with recurrent VVC history, though this is not standard practice
- Provide anticipatory guidance about yeast infection symptoms (itching, discharge, dyspareunia) so patients can seek early treatment
The standard treatment for antibiotic-associated VVC remains topical or oral azole antifungals per CDC guidelines 8, with fluconazole 150 mg single dose being the most convenient oral option.